PAR-22-225: NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
Closed
This grant is closed. A newer notice from the same program is open now: NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed) (PAR-27-082). Status: Due dates in the notice, expires May 25, 2029. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on September 7, 2025.
From the official notice on Grants.gov, last changed September 13, 2022. Checked November 7, 2026.
- Award amountsNot given on Grants.gov
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeP01
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$459,350
- Typical project length5 years
- P01, Research Program Project Grant. Several related research projects around one theme, with shared core facilities. Other open P01 notices.
Projects funded under PAR-22-225 were run by National Institute of Allergy and Infectious Diseases (NIAID, 45 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read PAR-22-225 in the NIH Guide.
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| PAR-27-082 | May 7, 2026 | Due dates in the notice, expires May 25, 2029 | Open |
Key dates
| Posted | September 13, 2022 |
|---|---|
| Deadline | September 7, 2025 |
| Archived by Grants.gov | October 13, 2025 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed.
Is this a realistic fit?
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
This Funding Opportunity Announcement (FOA) invites submission of investigator-initiated Program Project (P01) applications. The proposed programs should address scientific areas relevant to the NIAID mission including: biology and pathogenesis of infectious microbes, including HIV; host-microbe interactions; mechanisms regulating immune system development and function across the lifespan, and in response to infectious pathogens; immune dysfunction resulting in allergy, asthma, autoimmunity, immunodeficiency, or transplant rejection; and translational research to develop vaccines, therapeutics, and diagnostics to prevent and treat infectious and immune-mediated diseases. Each P01 application submitted to this FOA must include at least two related, synergistic research projects that share a common central theme, focus, and/or overall objective; and an administrative core. A P01 may include scientific cores, if needed for the proposed research.
Funded under PAR-22-225 so far
NIH funded 45 projects under PAR-22-225 in fiscal 2024 to 2026, at 32 institutions. The median yearly award was $459,350.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Admin Core | University of Minnesota | 2026 | $139,369 |
| Administrative Core | Sloan-Kettering Inst Can Research | 2026 | $130,272 |
| Administrative, Biostatistics and Bioinformatics Core A | University of Pittsburgh at Pittsburgh | 2026 | $84,919 |
| Administrative Core | University of Washington | 2026 | $388,432 |
| Microanalytics Core | Yale University | 2026 | $459,350 |
| Project 3 Determinants of Vaccine Efficacy | Univ of Massachusetts Med Sch Worcester | 2026 | $470,732 |
| Novel Mechanisms of Genetic Errors of Immunity | Washington University | 2026 | $2.5 million |
| Immunologic strategies to prevent congenital cytomegalovirus transmission and disease in rhesus monkeys | Weill Medical Coll of Cornell Univ | 2026 | $3.9 million |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Apply under the newer notice, PAR-27-082, which is open now.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is PAR-22-225 still open?
No. It closed on September 7, 2025. A newer notice is open: PAR-27-082, due dates in the notice, expires May 25, 2029.
Who can apply for NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)?
Closed September 7, 2025. Applications are no longer accepted; the program's newer notices are on this page when there are any.
Who has been funded under PAR-22-225?
NIH RePORTER lists 45 projects funded under PAR-22-225 in fiscal 2024 to 2026, at 32 institutions. The most were at Weill Medical Coll of Cornell Univ, Columbia University Health Sciences, Brigham and Women's Hospital.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)
- NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed)
- NIH Research Program Projects (Parent P01 Clinical Trial Optional)
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)